

## Lumito featured at AACR 2025

**The AACR Annual Meeting (American Association for Cancer Research) is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine.**

Lumito gained valuable visibility through a presentation by Professor Paul Waring at Akoya's Spotlight Theatre, where he introduced Lumito's SCIZYS platform and nanoparticle technology as a next-generation solution for precise and accurate biomarker quantification in tissue. Our presence at AACR strategically positions Lumito at the evolving diagnostic landscape, aligning with the future of targeted therapy development and cutting-edge research advancements.

"With the recent FDA approval of trastuzumab deruxtecan (Enhertu) for patients with advanced HR-positive, HER2-negative breast cancer, including those with low or ultralow HER2 expression, we're entering a new era of precision oncology," said Professor Paul Waring during his presentation at AACR in Chicago. "However, this shift brings a major challenge for pathologists: accurately quantifying HER2 expression at these very low levels using traditional DAB-based immunohistochemistry. The variability in detecting IHC 0, 1+, or 2+ makes it difficult to consistently determine which patients are truly eligible for Enhertu. What we urgently need are membrane-targeted solutions that offer greater accuracy and precision at the low and ultralow end of HER2 expression, similar to how HER2 FISH is used for ambiguous 2+ cases. I introduced Akoya's multiplex mIF breast cancer panel and stressed the importance of calibrating and orthogonally validating these results using highly sensitive, photostable, and autofluorescence-free technologies, like Lumito's unconverted nanoparticles and SCIZYS detection system. These advanced platforms have the potential to bring much-needed clarity to HER2 testing and improve patient selection for emerging targeted therapies."

"We're very pleased and grateful to have Professor Paul Waring as both an advisor and advocate for our technology," said Sanna Wallenborg, CEO of Lumito. "Paul brings deep insight into the drug development landscape and continually helps us refine our offering and strategic focus. He truly understands the challenges that come with introducing more targeted and potent therapies to market, and how SCIZYS and our nanoparticle-based platform can help meet that critical need."

**For further information, please contact:**

---

Sanna Wallenborg, CEO Lumito  
E-mail: [sw@lumito.se](mailto:sw@lumito.se)  
Ph: +4670-870 01 68

### **About Lumito**

Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. [www.lumito.se/en/](http://www.lumito.se/en/)

### **Attachments**

[Lumito featured at AACR 2025](#)